Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-week, Open-label, Randomized, Standard of Care Controlled, Dose-ranging Safety and Efficacy Study of Dovramilast in People With Moderate to Severe Acute or Recurrent Leprosy Type 2 Reaction

Next Previous
Trial Profile

A 12-week, Open-label, Randomized, Standard of Care Controlled, Dose-ranging Safety and Efficacy Study of Dovramilast in People With Moderate to Severe Acute or Recurrent Leprosy Type 2 Reaction

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dovramilast (Primary) ; Prednisolone; Thalidomide
  • Indications Leprosy
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Medicines Development for Global Health

Most Recent Events

  • 23 Dec 2025 Planned End Date changed from 1 Oct 2027 to 1 Dec 2027.
  • 23 Dec 2025 Planned primary completion date changed from 1 Dec 2026 to 1 Jan 2027.
  • 23 Dec 2025 Planned initiation date changed from 1 Oct 2025 to 1 Jan 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top